Biomarker Specialist Activiomics appoints Dr Trevor Nicholls as Non-Executive Chairman

28-Mar-2012 - United Kingdom

Activiomics Limited. has announced the appointment of industry leader Dr Trevor Nicholls to its Board as Non-Executive Chairman.

Dr Nicholls has over 30 years’ experience of building international businesses in the life science industry.  Currently he is CEO of CABI, a not-for-profit inter-governmental organisation owned by 46 member countries worldwide and is Non-Executive Chairman of Oxford Nanopore Technologies, which is developing the GridION system, a new generation of electronic molecular analysis system for use in scientific research, personalised medicine, crop science, and security/defence.   His previous board roles include Chief Commercial Officer of Affymetrix Inc, based in California and, prior to that, CEO of Oxagen, a UK biotech company where he raised £50m over three venture-backed financing rounds and secured major commercial partnerships and academic collaborations.

Other news from the department people

Most read news

More news from our other portals

Last viewed contents

Novartis inaugurates large-scale US based cell-culture influenza vaccine manufacturing facility - Facility designed to supply 150 million doses of pandemic vaccine within 6 months of influenza pandemic declaration

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Bonnie Bassler and Martin Wikelski receive Max Planck Research Award - Scientists honoured for their pioneering research into the sensory perception of organisms

Stora Enso and Gasum to make renewable energy from wastewater in Sweden

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

LDC and HZI enter partnership for the discovery of new drugs against multi-resistant bacteria

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

New model could revolutionise the treatment of autoimmune disease as well as vaccine development - Paradigm shift in immunology: 'Adaptive Tolerance' balances autoimmune reaction

Generex Biotechnology and Pevion Biotech announce plans for immunotherapeutic vaccine collaboration

Successful Outcome from European Clinical Pharmacokinetic Study Comparing SUBA-Itraconazole with Sporanox - HalcyGen to begin Marketing Authorisation Application for Regulators in Europe

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Eschbach receives the Best of Industry Award for Artificial Intelligence for the second time in a row - "AI technologies are increasingly becoming an integral part of process management..."

Antibiotic-Resistant Bacteria Have Evolved a Unique Chemical Mechanism, New Discovery Reveals

UF study strengthens concerns about long-term use of certain painkillers

Restoring chemotherapy sensitivity by boosting microRNA levels

Restoring chemotherapy sensitivity by boosting microRNA levels

Centocor, Inc. - Horsham, USA

Centocor, Inc. - Horsham, USA